PBA
EDIT icon

Paradigm Biocapital Advisors’s Editas Medicine EDIT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Buy
+5,586,625
New +$16.3M 0.34% 27

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Paradigm Biocapital Advisors's EDIT Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in Editas Medicine (EDIT) in Q2 2026: 5,586,625 shares worth $18.1M. The stake represents 0.34% of the portfolio and ranks #27 among its holdings.

187 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Paradigm Biocapital Advisors held 5,586,625 shares of Editas Medicine worth $18.1M as of Q2 2026.
  • Editas Medicine was a new Paradigm Biocapital Advisors position in Q2 2026.
  • Editas Medicine made up 0.34% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #27 holding.
  • 187 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.